基于决策树模型对我国5种常用非典型抗精神病药一线治疗首发精神分裂症的成本效果分析

发布时间：2018-06-13 09:09

本文选题：首发精神分裂症 + 非典型抗精神病药　；参考：《中国新药杂志》2017年17期

【摘要】：目的:运用药物经济学评价的方法,对利培酮、奥氮平、喹硫平、齐拉西酮、阿立哌唑5种药品一线治疗首发精神分裂症进行成本效果分析,为临床治疗首发精神分裂症用药提供参考和建议。方法:通过单组率Meta分析获得有效率指标,对5种药品治疗首发精神分裂症构建决策树模型进行成本效果分析,并进行单因素敏感性分析和概率敏感性分析。结果:通过增量成本效果分析,喹硫平、奥氮平、阿立哌唑为劣势方案被排除;齐拉西酮相比于利培酮的增量成本效果比(incremental cost effectiveness ratio,ICER)为25 194.09元。敏感性分析与基础分析结果基本一致。结论:临床治疗首发精神分裂症时可以根据患者的意愿支付值(willingness-to-pay,WTP)选择最优方案。若WTP低于ICER,则优先使用利培酮;若高于ICER,则优先使用齐拉西酮。但就我国国情而言,ICER值相对较高,利培酮对绝大多数中国患者更具有经济性,推荐临床优先使用。
[Abstract]:Objective: to evaluate the cost-effectiveness of risperidone, olanzapine, quinthiapine, ziprasidone and aripiprazole in first-line treatment of first-line schizophrenia. To provide reference and advice for clinical treatment of first episode schizophrenia. Methods: the effective rate index was obtained by single-group meta-analysis. The cost-effect analysis was performed on the decision tree model of five kinds of drugs for first-episode schizophrenia, and the single-factor sensitivity analysis and probability sensitivity analysis were carried out. Results: according to the incremental cost effect analysis, quinolipine, olanzapine and aripiprazole were excluded, and the incremental cost effect of ziprasidone compared with risperidone was 25 194.09 yuan. The results of sensitivity analysis are consistent with those of basic analysis. Conclusion: the optimal scheme can be selected according to the patient's will to pay for the first episode schizophrenia. Risperidone is preferred if WTP is lower than ICERand ziprasidone is preferred if WTP is higher than ICER. However, the ICER value of risperidone is relatively high in our country. Risperidone is more economical for most Chinese patients.
【作者单位】：中国药科大学国际医药商学院;
【分类号】：R956

【相似文献】